Capital Group Private Markets, a unit of U.S. investment firm Capital Group Companies, has led a US$90 million round in Chinese biotech firm Innovent Biologics, Inc. New investors in the round include Cormorant Asset Management, Rock Springs Capital and Ally Bridge Group as well as the existing investors Temasek, Hillhouse, Legend Capital, Lilly Asia Venture and Taikang Insurance, according to Innovent Biologics’ announcement. Founded in 2011, the company goal is to produce complex biopharmaceutical products designed to be affordable to … Capital Group Private Markets Leads $90M Round In China’s Innovent Biologics appeared first on China Money Network.